drugset / Trial / NCT01153724
Relative Bioavailability of Olodaterol and Fluconazole
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial is intended to investigate a possible effect of the CYP 2C9 inhibitor fluconazole on the bioavailability of olodaterol
Timeline
- Start
- 2010-05
- Primary completion
- 2010-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluconazole | Small molecule | 400 mg | — |
| Subject | Olodaterol | Small molecule | 10 ug | Inhaled |